(Q53274422)

English

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.

scientific article published on 18 January 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

phase II clinical trial

0 references

phase I clinical trial

0 references

author name string

Jorge A Garcia

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Tarek Mekhail

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Paul Elson

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Laura Wood

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Ronald M Bukowski

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Robert Dreicer

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Brian I Rini

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

publication date

18 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

BJU International

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

109

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

63-69

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

The human hematopoietic colony-stimulating factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Hematopoietic growth factors. Biology and clinical applications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2010.10011.X

21 January 2018

Identifiers

10.1111/J.1464-410X.2010.10011.X

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21244601

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53274422&oldid=1749510184"